Pharmasaga initiates Phase II clinical trials for PS1 diabetes drug
Pharmasaga has announced the advancement of its innovative small-molecule drug, PS1, into Phase II clinical trials. Following the successful completion of Phase I, the company plans to conduct trials for both Type 1 (T1D) and Type 2 (T2D) diabetes across the United States, China, Australia, and Taiwan.
PS1 targets PDIA4 and functions as an oral medication designed to maintain functional islet cells and protect remaining beta cells. This mechanism aims to potentially modify or reverse the progression of diabetes, addressing a significant unmet medical need. Current treatments primarily focus on blood sugar control and complication delay, whereas PS1 focuses on islet cell preservation.
Pharmasaga intends to submit Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) in early October 2026. The Phase II trials for T2D will evaluate the efficacy, safety, and tolerability of different dosages to achieve proof of concept, while the T1D trials will focus on maintaining endogenous insulin secretion by protecting beta cells from immune-driven damage.
Entities
International Diabetes Federation · PS1 · Pharmasaga · U.S. Food and Drug Administration
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 3 SOURCES] Phase I results showed good safety and potential efficacy. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] Clinical trials are planned for the United States, China, Australia, and Taiwan. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] The Phase II trials will cover both Type 1 and Type 2 diabetes. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] Phase I clinical trials for PS1 have been completed. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] Pharmasaga will submit IND applications to the FDA in early October 2026. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] Pharmasaga is initiating Phase II clinical trials for its small-molecule drug PS1. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] PS1 targets PDIA4 as its therapeutic target. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net
- [● 3 SOURCES] The mechanism of PS1 involves maintaining and protecting islet cells. www.ltvnews.net · pingtungtimes.com.tw · www.thehubnews.net